Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients

Inclusion Criteria: * All types of locally advanced and metastatic malignancy * Male/female participants * Age\>18 y.o. * Signed informed consent for participation in the study * No restriction on Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) Performance Status * Subject should not have received a prior systemic anti-viral treatment for Covid19 disease. Exclusion Criteria: * Patients with known hypersensitivity to hydroxychloroquine or chloroquine, azithromycin, erythromycin, or any other macrolide, ketolide or any of the excipients of the hydroxychloroquine and/or azithromycin-based specialty used. * Severe hepatic impairment and patients with severe cholestasis. * Patients with renal insufficiency with creatinine clearance \< 40 mL/min. * Combinations of drugs contraindicated in accordance with the approvals of the specialties used. * Patients currently treated with Tamoxifen * Patients already treated by hydroxychloroquine or azithromycin for Covid19 disease or currently treated with other antiviral drugs against coronavirus. * Patients with known contra-indication to treatment with the study drug, including retinopathy, G6PD deficiency, QT prolongation and severe hepato-cellular insufficiency. * Patients post allogeneic hematopoietic stem cell transplantation are eligible to the Part B treatments but the potential toxic effects of hydroxychloroquin and azithromycin on hematopoietic stem cells should be taken into consideration by prescribers. * Pregnant or breastfeeding women. Women of childbearing potential (WOCBP, as defined in appendix 2) should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.